Sign in

KLRA on Nasdaq

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Waltham, Massachusetts.1 Its shares trade on Nasdaq under the symbol KLRA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerKLRA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address180 Third Avenue, 4Th Floor, Waltham, Ma 024512
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Corporate structure

Kailera Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kailera Therapeutics, Inc.

  • Kailera Therapeutics, Inc. Waltham, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Kailera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ronald C. Renaud Jr.2026–now

President

  1. Ronald C. Renaud Jr.2026–now

Chief financial officer

  1. Douglas W. Pagan2026–now
Board members and other officers (14)

Timeline

  1. Aug 12, 20268-K Results of operations18
  2. May 26, 20268-K Results of operations19
  3. Apr 20, 20268-K Bylaws or fiscal year changed; Other events20
  4. Apr 16, 2026New chief executive Ronald C. Renaud Jr. becomes CEO3

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202621

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results18
  2. May 26, 2026Reported quarterly or annual results19

Drug trials and FDA: coming up

  1. May 2027Phase 2 trial readout expected Phase 2 trial of Ribupatide in Obesity: primary completion expected May 2027 (ClinicalTrials.gov NCT07458269).22
  2. Jul 7, 2027Phase 2 trial readout expected Phase 2 trial of KAI-7535 in Obesity: primary completion expected Jul 7, 2027 (ClinicalTrials.gov NCT07497880).23

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

62 filings to the SEC since October 2021: 2 quarterly reports, 3 major events, 42 insider forms, 5 large holders, 10 other. The latest 20:

  1. Sep 9, 20264 EDGAR
  2. Sep 9, 20263 EDGAR
  3. Aug 14, 2026SCHEDULE 13G EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 12, 202610-Q EDGAR
  6. Aug 12, 20268-K EDGAR
  7. Aug 5, 2026SCHEDULE 13G EDGAR
  8. Jul 8, 20264 EDGAR
  9. Jul 8, 20263 EDGAR
  10. Jun 11, 20264 EDGAR
  11. May 26, 202610-Q EDGAR
  12. May 26, 20268-K EDGAR
  13. Apr 23, 2026SCHEDULE 13D EDGAR
  14. Apr 23, 2026SCHEDULE 13D EDGAR
  15. Apr 22, 20264 EDGAR
  16. Apr 22, 20264 OWNERSHIP DOCUMENT EDGAR
  17. Apr 20, 20264 EDGAR
  18. Apr 20, 20264 EDGAR
  19. Apr 20, 20264 EDGAR
  20. Apr 20, 20264 EDGAR

The 62 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 20, 2026RTW INVESTMENTS, LP10% ownerBuy500,000$16.00$8.0MForm 4
Apr 20, 2026BCPE Perseus Investor, LP10% ownerBuy8,398,438$16.00$134.4MForm 4
Apr 20, 2026Koppel AdamDirectorBuy1,562,500$16.00$25.0MForm 4
Apr 20, 2026BCLS Fund IV Investments GP, LLC10% ownerBuy1,562,500$16.00$25.0MForm 4
Apr 20, 2026Kaplan Andrew T.DirectorBuy8,398,438$16.00$134.4MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 99. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bain Capital Investors LLC26,255,581$578.4M12.0%New
Bain Capital Life Sciences Investors, LLC22,583,268$497.5M29.6%New
Rtw Investments, LP10,776,820$237.4M2.0%New
Canada Pension Plan Investment Board7,304,688$160.9M0.1%New
Atlas Venture Life Science Advisors, LLC5,171,282$113.9M12.9%New
Fmr LLC3,970,865$87.5M0.0%New
BlackRock, Inc.3,928,604$86.5M0.0%New
Citadel Advisors LLC3,240,787$71.4M0.0%New
Adage Capital Partners Gp, L.l.c.3,208,286$70.7M0.1%New
Wellington Management Group Llp2,919,110$64.3M0.0%New
Royalty Pharma Sub-Manager, LLC2,455,357$54.1M22.4%New
Siren, L.L.C.2,214,286$48.8M1.0%New
Vanguard Capital Management LLC1,693,958$37.3M0.0%New
Vanguard Portfolio Management LLC1,652,507$36.4M0.0%New
Geode Capital Management, LLC1,133,115$25.0M0.0%New
Farallon Capital Management, L.l.c.1,100,000$24.2M0.1%New
Frazier Life Sciences Management, L.P.1,100,000$24.2M0.5%New
Trails Edge Capital Partners, LP984,786$21.7M3.4%New
UBS Group AG972,683$21.4M0.0%New
Jupiter Topco LLC970,857$21.3M0.0%New
Ameriprise Financial Inc821,331$18.1M0.0%New
Deep Track Capital, LP700,000$15.4M0.2%New
Eventide Asset Management, LLC616,720$13.6M0.2%New
Vestal Point Capital, LP575,000$12.7M0.3%New
Cormorant Asset Management, LP550,000$12.1M0.6%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Kailera Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKailera Therapeutics, Inc.1
  • CIK0002096997
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address180 Third Avenue, 4Th Floor, Waltham, MA 024511
  • Phone508-440-94751
  • Shares outstanding129,643,676 as of Aug 6, 202629
  • On EDGAR sinceDec 19, 20251
  • Filings62 in all: 3 (22), 4 (20), 8-K (3), SCHEDULE 13G (3), 10-Q (2), SCHEDULE 13D (2), 424B4 (1), 8-A12B (1)1
    All 16 form types

    CERT (1), DRS (1), DRS/A (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1)

  • Latest filingsQuarterly report (10-Q) Aug 12, 2026
    Latest 8-K (8-K) Aug 12, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29